NEW HAVEN: Alexion Pharmaceuticals, Inc. [NASDAQ: ALXN] is adding some bioscience chops to its board appointing Francois Nader, M.D.
The company says “Nader is an accomplished leader in the biopharmaceutical industry with a proven track record of building and transforming companies, launching rare disease therapies, and creating significant shareholder value.”
Just last week in an editorial recognizing the gaps in Alexion’s board, Business New Haven, Conntact.com called for an expansion of bioscience experience on the board, as the company seeks to create a new drug pipeline, dependent on licensing and or acquisitions.
Nader was President, CEO of NPS Pharma [NPS] from 2008 to 2015. Alexion says “Nader transformed the organization into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases.” The company was purchased by Shire Pharmaceuticals [NasdaqGS:SHPG] under his watch in 2015 for $5.2 billion.
Shire purchased Baxalta a spinoff of Baxter International in 2016, while under Hantson Ludwig [CEO], Alexion’s current CEO.
Nader currently serves as non-executive chairman of Acceleron Pharma, Inc. [Nasdag:XLRN] a small public biotech with a $1.6 billion market cap, focusing on drug development for rare diseases, based in Cambridge, Mass.
He is also on the boards of Advanced Accelerator Applications [Nasdaq: AAAP], Clementia Pharmaceuticals Inc. [Nasdaq: CMTA] of Montreal, Canada and private company ArRETT Neuroscience.
In the small world category, David Scheer board chairman of Alexion’s New Haven neighbor, Achillion Pharmaceuticals [Nasdaq: ACHN] is the board chairman and a founder of ArRett. Achillion has a drug [ACH 4771] in clinical trials that potentially is a competitor for Alexion’s lead drug Soliris in the treatment of Paroxysmal Nocturnal Hemoglobinuria [PNH].
David Brennan, Chairman of Alexion’s Board, commented, “Francois is a leading value-builder in the biotechnology industry with expertise in developing and delivering innovative therapies that address significant patient needs. His strong background in rare diseases across both commercial and R&D functions will be a valuable addition to our board.”
Nader added: “I look forward to applying my life sciences experience to help guide the company’s future growth and success.”